Published in Arch Intern Med on November 24, 2008
Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol (2009) 2.22
Triggers of hospitalization for venous thromboembolism. Circulation (2012) 1.76
Statin use and the risk of Clostridium difficile in academic medical centres. Gut (2012) 1.55
Cancer, clots and consensus: new understanding of an old problem. J Clin Oncol (2009) 1.35
The platelet as an immune cell-CD40 ligand and transfusion immunomodulation. Immunol Res (2009) 1.25
Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia. Ann Oncol (2012) 1.16
New frontiers in transfusion biology: identification and significance of mediators of morbidity and mortality in stored red blood cells. Transfusion (2011) 1.11
New insights into cancer-associated thrombosis. Arterioscler Thromb Vasc Biol (2009) 1.11
Venous thromboembolism in the patient with cancer: focus on burden of disease and benefits of thromboprophylaxis. Cancer (2010) 1.10
Epoetin-beta treatment in patients with cancer chemotherapy-induced anaemia: the impact of initial haemoglobin and target haemoglobin levels on survival, tumour progression and thromboembolic events. Br J Cancer (2009) 1.09
Platelet proteome changes associated with diabetes and during platelet storage for transfusion. J Proteome Res (2009) 1.07
A systematic review of the effect of red blood cell transfusion on mortality: evidence from large-scale observational studies published between 2006 and 2010. BMJ Open (2013) 1.00
Platelet transfusions: impact on hemostasis, thrombosis, inflammation and clinical outcomes. Thromb Res (2010) 0.97
A European patient record study on diagnosis and treatment of chemotherapy-induced anaemia. Support Care Cancer (2014) 0.92
Thromboprophylaxis with low-molecular-weight heparin in medical patients with cancer. Cancer (2009) 0.90
Cancer and venous thromboembolic disease: from molecular mechanisms to clinical management. Curr Oncol (2014) 0.88
Intravenous iron alone resolves anemia in patients with functional iron deficiency and lymphoid malignancies undergoing chemotherapy. Med Oncol (2014) 0.87
Prevention of venous thromboembolism in hospitalized patients with cancer. J Clin Oncol (2009) 0.85
Platelet transfusion - the new immunology of an old therapy. Front Immunol (2015) 0.84
Platelet transfusions: trigger, dose, benefits, and risks. F1000 Med Rep (2010) 0.84
Transfusion of red cells in hematopoietic stem cell transplantation (TRIST): study protocol for a randomized controlled trial. Trials (2011) 0.83
Hemostasis in liver transplantation: Pathophysiology, monitoring, and treatment. World J Gastroenterol (2016) 0.81
The central role of extracellular vesicles in the mechanisms of thrombosis in paroxysmal nocturnal haemoglobinuria: a review. J Extracell Vesicles (2014) 0.81
Isoprostane and isofuran lipid mediators accumulate in stored red blood cells and influence platelet function in vitro. Transfusion (2013) 0.81
Use of blood products and risk of stroke after coronary artery bypass surgery. Blood Transfus (2012) 0.81
Guidelines for treatment and prevention of venous thromboembolism among patients with cancer. Thromb Res (2014) 0.80
Thrombosis, cancer and renal insufficiency: low molecular weight heparin at the crossroads. Support Care Cancer (2012) 0.80
Platelet storage and transfusions: new concerns associated with an old therapy. Drug Discov Today Dis Mech (2011) 0.80
Post-diagnosis hemoglobin change associates with overall survival of multiple malignancies - results from a 14-year hospital-based cohort of lung, breast, colorectal, and liver cancers. BMC Cancer (2013) 0.79
Red blood cell transfusion triggers in acute leukemia: a randomized pilot study. Transfusion (2016) 0.79
Venous thromboembolism in the cancer population: pathology, risk, and prevention. J Adv Pract Oncol (2012) 0.79
Impact of preoperative anemia on relapse and survival in breast cancer patients. BMC Cancer (2014) 0.79
A Randomized Noninferiority Trial of Intravenous Iron Isomaltoside versus Oral Iron Sulfate in Patients with Nonmyeloid Malignancies and Anemia Receiving Chemotherapy: The PROFOUND Trial. Pharmacotherapy (2016) 0.78
Cancer and Venous Thromboembolic Disease: A Review. Oncologist (2017) 0.78
Enhancing uniformity and overall quality of red cell concentrate with anaerobic storage. Blood Transfus (2017) 0.77
Risk of venous thromboembolism in cancer patients treated with epoetins or blood transfusions. Br J Clin Pharmacol (2016) 0.77
Platelet Activation Following Exposure to Anti-ABO Antibodies-An In Vitro Study. US Oncol Hematol (2011) 0.77
Statin islands and PPAR ligands in platelets. Arterioscler Thromb Vasc Biol (2009) 0.77
Resveratrol preserves the function of human platelets stored for transfusion. Br J Haematol (2015) 0.77
Association of Pretreatment Anemia with Pathological Response and Survival of Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: A Population-Based Study. PLoS One (2015) 0.76
Clinical problem solving: utility of sonography in oncologic patients. J Ultrasound Med (2014) 0.76
A Validated Risk Score for Venous Thromboembolism Is Predictive of Cancer Progression and Mortality. Oncologist (2016) 0.75
Impact of a Patient Blood Management Program and an Outpatient Anemia Management Protocol on Red Cell Transfusions in Oncology Inpatients and Outpatients. Oncologist (2016) 0.75
Should Prophylactic Anticoagulation Be Considered with Large Uterine Leiomyoma? A Case Series and Literature Review. Case Rep Obstet Gynecol (2016) 0.75
Superior vena cava syndrome and colon carcinoma: a report of a multifactorial association. Case Rep Oncol Med (2015) 0.75
Venous Thromboembolism in Cancer: An Update of Treatment and Prevention in the Era of Newer Anticoagulants. Front Cardiovasc Med (2016) 0.75
Recurrent leiomyosarcoma presenting as malignant arterial tumor thrombus. Gynecol Oncol Case Rep (2013) 0.75
Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem cell support. Cochrane Database Syst Rev (2017) 0.75
Is there any role of intravenous iron for the treatment of anemia in cancer? BMC Cancer (2016) 0.75
Deep vein thrombosis in medical and surgical Intensive Care Unit patients in a Tertiary Care Centre in North India: Incidence and risk factors. J Anaesthesiol Clin Pharmacol (2017) 0.75
Costs of care for lung and colon cancer patients receiving chemotherapy following FDA policy changes. Support Care Cancer (2014) 0.75
A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med (1999) 20.31
Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA (2005) 6.16
Validity of information on comorbidity derived rom ICD-9-CCM administrative data. Med Care (2002) 5.92
Blood transfusion in elderly patients with acute myocardial infarction. N Engl J Med (2001) 5.43
Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA (2004) 5.11
Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol (2005) 4.82
Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med (2006) 4.10
Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst (2006) 3.23
S-nitrosohemoglobin deficiency: a mechanism for loss of physiological activity in banked blood. Proc Natl Acad Sci U S A (2007) 2.77
Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med (1998) 2.58
Platelet transfusions during coronary artery bypass graft surgery are associated with serious adverse outcomes. Transfusion (2004) 2.51
Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer (2005) 2.20
Prevalence and outcomes of anemia in cancer: a systematic review of the literature. Am J Med (2004) 2.04
Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb Haemost (2002) 1.99
The epidemiology of diagnosed pulmonary embolism and deep venous thrombosis in the elderly. Arch Intern Med (1994) 1.96
Deep venous thrombosis in medical-surgical critically ill patients: prevalence, incidence, and risk factors. Crit Care Med (2005) 1.87
Accuracy of coding for possible warfarin complications in hospital discharge abstracts. Thromb Res (2005) 1.87
Association of age, sex, and race with body iron stores in adults: analysis of NHANES III data. Am Heart J (2000) 1.68
Human bone marrow megakaryocytes and platelets express PPARgamma, and PPARgamma agonists blunt platelet release of CD40 ligand and thromboxanes. Blood (2004) 1.55
Risk factors and clinical impact of postoperative symptomatic venous thromboembolism. J Vasc Surg (2007) 1.47
Platelet derived CD154 (CD40 ligand) and febrile responses to transfusion. Lancet (2001) 1.29
An association of soluble CD40 ligand (CD154) with adverse reactions to platelet transfusions. Transfusion (2006) 1.28
Effect of blood transfusion on outcome after pancreaticoduodenectomy for exocrine tumour of the pancreas. Br J Surg (2007) 1.03
Cancer incidence in blood transfusion recipients. J Natl Cancer Inst (2007) 0.97
Association between venous thromboembolism and perioperative allogeneic transfusion. Arch Surg (2007) 0.91
Transfusion utilization during adnexal or peritoneal cancer surgery: effects on symptomatic venous thromboembolism and survival. Gynecol Oncol (2005) 0.85
Hypercoagulability preceding cancer. The iron hypothesis. J Thromb Haemost (2005) 0.84
The effect of preoperative donation of autologous blood on deep-vein thrombosis after total hip arthroplasty. J Bone Joint Surg Br (2001) 0.83
2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol (2006) 11.26
Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol (2011) 7.24
Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol (2013) 5.56
American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol (2007) 5.36
Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer (2006) 5.03
Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med (2008) 4.71
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol (2012) 4.42
Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood (2008) 4.06
Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol (2007) 4.06
American Society of Clinical Oncology 2013 top five list in oncology. J Clin Oncol (2013) 4.03
Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis. Cancer (2006) 3.86
Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer (2007) 3.27
Retracted Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. JAMA (2008) 3.26
Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer (2004) 3.15
Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation (2013) 3.02
Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies. J Clin Oncol (2011) 2.76
NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives. J Natl Compr Canc Netw (2011) 2.73
Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer (2011) 2.67
Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer. Am J Manag Care (2005) 2.37
Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty (2008) 2.30
Undertreatment of obese women receiving breast cancer chemotherapy. Arch Intern Med (2005) 2.25
Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer (2005) 2.20
Effect of patient socioeconomic status and body mass index on the quality of breast cancer adjuvant chemotherapy. J Clin Oncol (2006) 2.17
Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol (2005) 2.13
The intention-to-treat principle in clinical trials and meta-analyses of leukoreduced blood transfusions in surgical patients. Transfusion (2007) 2.12
Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol (2006) 2.03
Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. J Clin Oncol (2012) 2.02
Subsequent malignancies in children treated for Hodgkin's disease: associations with gender and radiation dose. Int J Radiat Oncol Biol Phys (2008) 1.95
Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens. J Clin Oncol (2007) 1.92
Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. Clin Cancer Res (2007) 1.87
Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA (2005) 1.87
Triggers of hospitalization for venous thromboembolism. Circulation (2012) 1.76
Thy-1 expression in human fibroblast subsets defines myofibroblastic or lipofibroblastic phenotypes. Am J Pathol (2003) 1.75
American Society of Clinical Oncology clinical practice guidelines: opportunities and challenges. J Clin Oncol (2008) 1.75
Heparin inhibition of endothelial cell proliferation and organization is dependent on molecular weight. Arterioscler Thromb Vasc Biol (2003) 1.67
Washing red blood cells and platelets transfused in cardiac surgery reduces postoperative inflammation and number of transfusions: results of a prospective, randomized, controlled clinical trial. Pediatr Crit Care Med (2012) 1.67
Leukocytosis, thrombosis and early mortality in cancer patients initiating chemotherapy. Thromb Res (2010) 1.66
Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. J Natl Compr Canc Netw (2008) 1.65
Allogeneic blood transfusions explain increased mortality in women after coronary artery bypass graft surgery. Am Heart J (2006) 1.62
Oral direct thrombin inhibitor ximelagatran compared with warfarin for the prevention of venous thromboembolism after total knee arthroplasty. J Bone Joint Surg Am (2005) 1.59
Hospital variation in transfusion and infection after cardiac surgery: a cohort study. BMC Med (2009) 1.58
Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. Ann Surg Oncol (2012) 1.56
Human bone marrow megakaryocytes and platelets express PPARgamma, and PPARgamma agonists blunt platelet release of CD40 ligand and thromboxanes. Blood (2004) 1.55
Transfusion of cell saver salvaged blood in neonates and infants undergoing open heart surgery significantly reduces RBC and coagulant product transfusions and donor exposures: results of a prospective, randomized, clinical trial. Pediatr Crit Care Med (2013) 1.55
A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications. Cancer (2007) 1.54
Autologous transfusion. BMJ (2002) 1.52
Impact of ABO mismatching on the outcomes of allogeneic related and unrelated blood and marrow stem cell transplantations for hematologic malignancies: IPD-based meta-analysis of cohort studies. Transfusion (2009) 1.47
Impact of venous thromboembolism and anticoagulation on cancer and cancer survival. J Clin Oncol (2009) 1.45
Aspirin resistance following pediatric cardiac surgery. Thromb Res (2010) 1.42
Large Variation in Blood Transfusion Use After Colorectal Resection: A Call to Action. Dis Colon Rectum (2016) 1.40
Building the evidence base for decision making in cancer genomic medicine using comparative effectiveness research. Genet Med (2012) 1.39
Variation in the cost of medications for the treatment of colorectal cancer. Am J Manag Care (2008) 1.39
Length of stay and mortality associated with febrile neutropenia among children with cancer. J Clin Oncol (2005) 1.38
Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review. J Clin Oncol (2010) 1.36
Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. Cancer (2010) 1.34
Impact of disease risk on efficacy of matched related bone marrow transplantation for pediatric acute myeloid leukemia: the Children's Oncology Group. J Clin Oncol (2008) 1.27
Cost-effectiveness of the children's oncology group long-term follow-up screening guidelines for childhood cancer survivors at risk for treatment-related heart failure. Ann Intern Med (2014) 1.27
Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy. Breast Cancer Res Treat (2006) 1.25
The platelet as an immune cell-CD40 ligand and transfusion immunomodulation. Immunol Res (2009) 1.25
Undertreatment of cancer patients with chemotherapy is a global concern. J Oncol Pract (2008) 1.23
Myeloid growth factors. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2007) 1.23
Transfusion immunomodulation--the case for leukoreduced and (perhaps) washed transfusions. Blood Cells Mol Dis (2012) 1.22
Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action. J Clin Oncol (2009) 1.21
Chemotherapy-induced alopecia: psychosocial impact and therapeutic approaches. Support Care Cancer (2004) 1.16
Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy. Value Health (2008) 1.14
Biosimilars: are they ready for primetime in the United States? J Natl Compr Canc Netw (2011) 1.14
Myelotoxicity and dose intensity of chemotherapy: reporting practices from randomized clinical trials. J Natl Compr Canc Netw (2003) 1.14
Platelets and megakaryocytes contain functional nuclear factor-kappaB. Arterioscler Thromb Vasc Biol (2009) 1.13
Myeloid growth factors. J Natl Compr Canc Netw (2013) 1.13
American Society of Clinical Oncology Clinical Practice Guidelines: formal systematic review-based consensus methodology. J Clin Oncol (2012) 1.12
Peroxisome proliferator-activated receptor gamma and retinoid X receptor transcription factors are released from activated human platelets and shed in microparticles. Thromb Haemost (2008) 1.12
Lymphatic mapping and sentinel lymph node biopsy in patients with melanoma: a meta-analysis. J Clin Oncol (2011) 1.12
Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy. Cancer (2007) 1.11